Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) generates news primarily around the clinical and regulatory progress of GLSI-100, its investigational immunotherapy to prevent breast cancer recurrences, and the Phase III FLAMINGO-01 trial. Company press releases highlight milestones in patient screening and enrollment, preliminary clinical observations, regulatory designations, and trial expansion across the United States and Europe.
Readers following GLSI news can expect updates on FLAMINGO-01, including the number of patients screened, enrollment status in the HLA-A*02 and non-HLA-A*02 arms, and preliminary analyses of recurrence rates, immune responses, and safety. The company has reported that more than 1,000 patients have been screened and that the 250-patient non-HLA-A*02 open label arm is fully enrolled, with early analyses suggesting an approximately 80% reduction in recurrence rate after completion of the primary immunization series. These observations are described by the company as preliminary and subject to change as the trial matures.
News items also cover regulatory developments, such as the U.S. FDA granting Fast Track designation for GLSI-100 in the HLA-A*02 genotype population, and geographic expansion of FLAMINGO-01 into additional European countries, including Ireland, Portugal, Belgium, and Austria, following approvals from European regulators. Corporate strategy communications discuss clinical strategy, financing approaches such as at-the-market offerings, partnering activities, and oversight by the Data Safety Monitoring Board and Steering Committee.
For investors, clinicians, and observers, the GLSI news feed offers a consolidated view of how Greenwich LifeSciences describes the evolution of its lead program, including trial design refinements, interactions with regulators, and key governance decisions disclosed through SEC filings and press releases. Regularly reviewing these updates can help track the company’s reported progress in developing GLSI-100 for HER2-positive breast cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Greenwich LifeSciences (NASDAQ: GLSI) provided a year-end update on its clinical-stage immunotherapy, GLSI-100, aimed at preventing breast cancer recurrences. The company is expanding the Flamingo-01 Phase III trial, currently involving 20 US clinical sites recruiting patients, with plans to add 60-75 sites in Europe. CEO Snehal Patel expressed optimism from meetings at the 2022 SABCS and announced commercial manufacturing efforts for GP2, aiming to produce approximately 200,000 doses. A new patent application was filed regarding GP2’s use in immune response assays, enhancing the company's intellectual property portfolio.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced an extension to the lock-up period for shares owned by directors, officers, and pre-IPO investors until December 31, 2023, approximately 39 months post-IPO. The company is focused on developing GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences in patients post-surgery. The ongoing Phase III clinical trial, Flamingo-01, will evaluate the safety and efficacy of GLSI-100 in HER2/neu positive breast cancer patients. The trial aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.
Greenwich LifeSciences (GLSI) announced the launch of its Phase III clinical trial, Flamingo-01, aimed at evaluating the immunotherapy GLSI-100 for HER2/neu positive breast cancer patients. The trial, which commenced screening and enrollment at multiple sites, follows promising Phase IIb results showing 100% disease-free survival. The Company is entering pre-commercialization activities, including preparing for a BLA submission and initiating large-scale manufacturing. Key milestones include future presentations of trial data and ongoing licensing discussions.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has initiated the Flamingo-01 Phase III clinical trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences post-surgery. Clinical site activation is in progress across multiple hospitals, alongside site initiation training for clinical staff. The trial intends to enroll approximately 500 patients, with initial Phase III data expected by year-end. The company maintains a strong cash position, allowing for strategic financial maneuvers. CEO Snehal Patel indicated that results from the trial could validate prior Phase IIb findings, which showed no recurrences in treated patients over 5 years.
Greenwich LifeSciences (NASDAQ: GLSI) announced its well-capitalized status with a cash balance of $19.7 million as of March 31, 2022. The company aims to transition to an investment banking syndicate through a recent ATM sale agreement to use opportunistically. The commencement of the Phase III clinical trial, Flamingo-01, is expected to gradually increase the burn rate. Updates on the trial and ongoing studies will be provided soon, with a focus on immunotherapy GLSI-100 for breast cancer prevention.